Our CEO, Dr James Garner discussed the significance of the interim efficacy data from Kazia’s phase II trial of GDC-0084 in glioblastoma in an interview with Proactive Investors.
In the interview, Dr Garner talks about:
- How the median progression-free survival rate of 8.3 months strongly suggests that GDC-0084 is delaying the progression of glioblastoma in the patients treated
- How the data signals that GDC-0084 may be extending life expectancy for the patients treated
- How the data compares to the existing treatment option for glioblastoma, temozolomide
- The next steps for the phase II study and Kazia more generally
Watch the video interview here
About KaziaTherapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.